Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer

Eric D. Bernstein, Scott M. Herbert, Nasser H. Hanna

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

Background: Surgical resection remains the cornerstone of therapy for early-stage disease and offers the best chance for cure. Local and distant failure rates, however, remain unacceptably high with surgery alone. Radiation and systemic chemotherapy have been used to reduce recurrences in early-stage disease. Neoadjuvant and adjuvant strategies both offer sound theoretical benefit, but evidence supporting this has been lacking. The publication of a meta-analysis in 1995 triggered a reevaluation of adjuvant chemotherapy. Four randomized trials reported in the last 2 years support the use of adjuvant platinum-based chemotherapy. Methods: This article reviews the history of clinical trials evaluating neoadjuvant and adjuvant therapy in non-small-cell lung cancer. Results: Adjuvant chemotherapy improves 5-year survival rates by approximately 5%-15% compared with surgery alone. Conclusions: Surgical resection followed by adjuvant chemotherapy is the standard of care treatment for patients with completely resected stage I, II, and IIIA non-small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)291-301
Number of pages11
JournalAnnals of Surgical Oncology
Volume13
Issue number3
DOIs
StatePublished - Mar 1 2006

Keywords

  • Adjuvant chemotherapy
  • Lung neoplasms
  • Non-small-cell lung carcinoma
  • Radiotherapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this